Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To evaluate the efficacy and safety of low-dose rituximab (RTX) in the treatment of pemphigus.
Methods: A systematic literature search was conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov to identify eligible studies. Primary efficacy outcomes included complete remission (CR), relapse rates, time to disease control (TDC), time to CR, and cumulative corticosteroid dose. Safety outcomes were assessed by meticulously documenting adverse events (AEs) and concomitant medications reported in each study.
Results: The final analysis incorporated five comparative studies and nine single-arm studies investigating the efficacy and safety outcomes of low-dose RTX. Comparative data revealed no statistically significant differences between the high-dose and low-dose RTX groups in CR, relapse rates, TDC, time to CR, and cumulative corticosteroid dose. In single-arm studies, pooled CR and relapse rates were 63.2% and 28.6%, respectively. No fatal events were reported; however, severe AEs, including pneumonia and sepsis, were documented in the low-dose RTX cohort.
Conclusion: Low-dose RTX exhibited comparable clinical efficacy to high-dose RTX regimens in pemphigus management. However, clinicians should remain vigilant for potential AEs associated with low-dose RTX infusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331757 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1605243 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.
Ren Fail
December 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study.
[Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome].
Zhongguo Dang Dai Er Ke Za Zhi
August 2025
Department of Renal Immunology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, China.
Objectives: To investigate the clinical efficacy and safety of low-dose rituximab (RTX) (<375 mg/m²) maintenance therapy in children with primary nephrotic syndrome (PNS).
Methods: A retrospective analysis was conducted on the clinical data of PNS children who received low-dose RTX therapy at the Department of Renal Immunology, Children's Hospital of Soochow University from July 2016 to March 2024. Remission rate, recurrence frequency, corticosteroid and tacrolimus usage, and adverse reactions before and after RTX treatment were analyzed.
A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.
Front Immunol
August 2025
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Purpose: This study summarized the clinical and immunological characteristics of patients with muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MG), compared their difference with acetylcholine receptor (AChR) antibody-positive MG, and evaluated the therapeutic efficacy of rituximab (RTX) in MuSK-MG.
Methods: This study included 10 MuSK-MG patients and 10 new-onset AChR-MG patients. Clinical and immunological data were collected from medical records before RTX treatment.
Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis.
Front Immunol
August 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Objective: To evaluate the efficacy and safety of low-dose rituximab (RTX) in the treatment of pemphigus.
Methods: A systematic literature search was conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov to identify eligible studies.
Low Dose Vs Conventional Rituximab Regimen in Pemphigus Vulgaris - A Retrospective Single Centre Comparative Analysis to Assess the Clinical Efficacy and Cost-Effectiveness.
Indian Dermatol Online J
April 2025
Department of Dermatology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Background: Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), a B-cell-mediated autoimmune bullous disease. However, no clear consensus on the optimum dosage has been achieved yet.
Objectives: To compare the clinical efficiency and cost-effectiveness of a low-dose (RTX 2×500mg) vs conventional (RTX 2×1g) RTX regimen.